GET DAILY SIGNALSWhy Is Celcuity (CELC) Stock Down -22% Today?
Key Takeaways
- CELC shares are falling sharply in premarket trading on June 2, 2026, declining approximately 22% from the prior session's close of $126.18, implying a premarket price near $98.42
- The primary catalyst is the full detailed data presentation from the PIK3CA mutant cohort of Celcuity's Phase 3 VIKTORIA-1 clinical trial, delivered at the ASCO Annual Meeting in Chicago on June 2 — a long-anticipated event that appears to have triggered a "sell the news" reaction
- The stock had already rallied dramatically in the months leading up to today on positive topline data, leaving shares particularly vulnerable to a sentiment reversal once concrete details were disclosed
- Broader biotech sector volatility around major clinical data readouts adds to the pressure, as investors reassess risk/reward after an extended run-up
- The FDA's PDUFA decision for gedatolisib in the PIK3CA wild-type indication, expected by July 17, 2026, remains the next significant regulatory milestone traders are monitoring
Opening Summary
Celcuity Inc. (CELC) is a Minneapolis-based clinical-stage biotechnology company focused on developing targeted cancer therapies, most notably gedatolisib, a pan-PI3K and mTORC1/2 inhibitor being evaluated for hormone receptor-positive, HER2-negative advanced breast cancer. Shares are down approximately 22% in Tuesday premarket trading, falling from a prior close of $126.18 to an implied level near $98.42. The steep decline follows the presentation of detailed Phase 3 VIKTORIA-1 data at the ASCO Annual Meeting, an event the market had long anticipated and which now appears to have catalyzed significant profit-taking and recalibration of investor expectations.
ASCO Data Presentation and "Sell the News" Dynamics
Celcuity had announced topline results from the PIK3CA mutant cohort of VIKTORIA-1 on April 30, 2026, confirming that the gedatolisib triplet and doublet regimens achieved statistically significant and clinically meaningful improvements in progression-free survival versus alpelisib plus fulvestrant. That announcement sent shares sharply higher, as did prior trial readouts, contributing to a stock that had rallied over 1,000% over the preceding twelve months. The full granular data — including precise hazard ratios, median PFS numbers by arm, subgroup analyses, and a complete safety breakdown — were reserved for the June 2 late-breaking abstract oral session at ASCO. When detailed data is dissected in real time by oncologists, investors, and analysts, even technically positive results can disappoint when specific metrics fail to clear the bar that a dramatically re-rated stock has priced in.
Clinical Data Context
The VIKTORIA-1 trial's PIK3CA mutant cohort evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- locally advanced or metastatic breast cancer who had progressed on prior CDK4/6 inhibitor and aromatase inhibitor therapy. Both the triplet and doublet regimens demonstrated statistically significant PFS improvement over alpelisib and fulvestrant, and both were generally well tolerated with no new safety signals. However, comparisons within the biotech investment community scrutinize not just statistical significance but effect size, comparator arm selection, and how data stacks up relative to competing agents — factors that become fully visible only at an ASCO presentation, and can recalibrate even a clinically meaningful outcome into a relative disappointment against the market's elevated pricing.
Market Context and Trading Activity
CELC's prior close of $126.18 already reflected substantial speculative premium built up over months of anticipatory trading ahead of ASCO. Volume on June 1 was notably subdued at 753,136 shares versus an average of approximately 870,000, suggesting many investors had already positioned ahead of the event and were poised to react swiftly to the data. Biotech stocks tied to late-stage oncology readouts historically experience exaggerated post-ASCO moves — both up and down — because the event represents the culmination of a long-building news cycle, leaving the stock with limited near-term catalysts to sustain valuation once the data is public. Broader biotech sector ETFs and peers with similar PAM-pathway or breast cancer exposure may face sympathetic pressure as the market reassesses the competitive landscape.
Trending AI Robots
For traders navigating high-volatility events like clinical data readouts, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers across multiple strategies, timeframes, and asset classes, but only the top performers — ranked by recent metrics — appear in this Trending section. Bots vary widely in their approach, from momentum and swing strategies to mean-reversion and sector rotation, with each designed for a specific market environment. Traders looking to complement their own research with algorithmic tools may find this resource a useful starting point.
What Comes Next for CELC
The most immediate catalyst on the horizon is the FDA's PDUFA decision date for gedatolisib in the PIK3CA wild-type HR+/HER2- advanced breast cancer indication, expected by July 17, 2026 — a distinct regulatory milestone from today's mutant-cohort data. Approval would mark gedatolisib's first commercial launch and could materially alter the company's trajectory, while a Complete Response Letter would likely extend the sell-off. For the PIK3CA mutant indication, Celcuity has stated it intends to submit a supplemental New Drug Application (sNDA) to the FDA using today's VIKTORIA-1 data, with submissions to other regulatory authorities to follow. The next earnings report is scheduled for August 13, 2026, where management is expected to address pipeline progress and cash runway. CELC remains a pre-revenue, clinical-stage company reporting consistent net losses — $52.8 million in Q1 2026 alone — making it highly sensitive to trial outcomes and regulatory decisions. Analyst price targets and ratings revisions following the ASCO presentation will be closely watched in the sessions ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for CELC turns negative, indicating new downward trend
CELC saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 88 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 62 cases where CELC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELC entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CELC's RSI Indicator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CELC just turned positive on October 22, 2026. Looking at past instances where CELC's MACD turned positive, the stock continued to rise in 45 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Following a +9.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELC advanced for three days, in 249 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CELC's P/B Ratio (-255.705) is very low in comparison to the industry average of (3.498). P/E Ratio (-15.533) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CELC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company develops novel diagnostic tests
Industry Biotechnology
Advertisement